Pharming Group N.V. PHAR
12.30 USD -0.16 (-1.28%)
At closeNov 6, 2026, 4:00 AM EST
12.15 -0.15 -1.22%
Pre-market · Nov 6, 4:00 AM ET
12.13 Day range 12.72
9.11 52-week range 21.34
- YTD
- -30.39%
- 1 year
- -16.33%
News
globenewswire.com MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.
fool.com Pharming: 3 Key Takeaways for Long-Term Investors A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.
benzinga.com Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41 Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.
benzinga.com Pharming Q3 2026 Earnings Call Transcript Pharming (NASDAQ:PHAR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
benzinga.com Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per…
benzinga.com Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but Selective Insurance surged after beating EPS estimates, approving a $200M buyback and raising its dividend.
benzinga.com Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings U.S. stocks fell, led by a 2% Nasdaq drop; Lockheed Martin beat estimates and raised guidance. Oil rose, while global markets and metals declined.
benzinga.com Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Healthcare Services Group jumped 8.2% on an earnings beat. Biohaven led gainers, surging 30.5% after FDA news.- benzinga.com Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
- benzinga.com Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in…
benzinga.com Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was…